Navigation Links
Inactivation of Rad9 in Tumor Cells Would Be Advantageous In Cancer Therapy

A study conducted by Tej K. Pandita, Ph.D., associate professor of radiation oncology at Siteman Cancer Center, Washington University School of Medicine and Barnes-Jewish Hospital said that // inactivation of mammalian Rad9 in Tumor Cells Would Be Advantageous In Cancer Therapy.

Rad9 checks for DNA damage, and fixes dangerous breaks in the DNA double helix. It is active in telomeres which are the protective ends of chromosomes.

Hence Rad9 has gained a lot of importance in the research field as a potential target for cancer therapy.

Inactivation of Rad9 enhances the power of radiation treatments by making it easier for radiation to inflict fatal damage to a tumor cell. The findings were published in the journal Molecular and Cellular Biology.

It was found that Rad9 proteins interact with chromosomes telomeres. Telomerase are structures at the ends of chromosomes which protects the chromosome from fusion or degradation.

Rad9 proteins interact with proteins called telomere binding proteins. During the experiment if Rad9 in human cells were inactivated it resulted in damaging the chromosomes and caused end-to-end fusion at telomeres.

This disrupted the cell cycle and caused cell death. Because radiation treatments increase these incidents, loss of Rad9 in cancer cells could enhance the killing effect of radiation. Hence from this study it is evident that Rad9 directs the repair of DNA damage.

Further research has to be conducted on how Rad9 stabilizes the telomeres. It is thought that in the absence of Rad9 certain proteins associated with the telomeric structure become delocalized thereby exposing the DNA at the ends of chromosomes.

This research also would help in identifying people with mutations in Rad9 as these mutations could predispose a person to cancer because it results in genomic instability and result in cancer.

These fusions at the telomeric ends of c hromosomes are frequently seen in tumor tissues. In conclusion Rad9 functions both as a key factor to prevent tumor formation and also can be exploited in cancer therapy.

Related medicine news :

1. Use of Cellular Phones associated with Increased risk of Brain Tumors
2. Radiofrequency Energy Cooks Tumors Without Surgery
3. New Liver Tumor Treatment
4. Latest Tumor Classification More Informative
5. New Technique For Benign Breast Tumors
6. Another Treatment Option for Benign Tumors
7. Understanding The Origin Of Tumors
8. Outpatient Treatment Possible For Patients with Uterine Fibroid Tumors
9. Stem Cells, Tumor Cells Share Similar Properties: Scope For Treatment and Prevention?
10. Lipoma Arborescens: A Rare Tumor Of The Knee
11. Researchers Develop Mouse Model Of Brain Tumor
Post Your Comments:

(Date:10/13/2017)... York, NY (PRWEB) , ... October 13, 2017 , ... ... influential people in business to advocate for action towards gender equality at their inaugural ... views from around the globe, and reached a social audience of over 3 million. ...
(Date:10/13/2017)... ... 13, 2017 , ... Coveros, a leader in agile coaching ... contract by the Center for Medicare and Medicaid Services (CMS). The Enterprise Agile ... of Agile methodologies in a consistent and high value manner across CMS programs. ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco dentists, ... cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated to ... breathing. Oral appliances can offer significant relief to about 75 percent of people ...
(Date:10/12/2017)... ... , ... The American College of Medical Informatics (ACMI) will present the 2017 ... Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium is ... pioneer in the field of medical informatics, this prestigious award is presented to an ...
(Date:10/12/2017)... ... ... HMP , a leader in healthcare events and education, today announced that ... ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & Ozzie Awards luncheon ... editorial and design excellence across a range of sectors. This year’s program included the ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... , Sept. 27, 2017  Commended for their devotion ... notable awards. Ranked as number one in the South Florida ... time in Inc. 5000 yearly list, the national specialty pharmacy ... Armando Bardisa will soon be honored by SFBJ ... Set to receive his award in ...
(Date:9/25/2017)... 25, 2017   Montrium , an industry ... today—from the IQPC Trial Master Files & Inspection ... that EastHORN Clinical Services has selected eTMF ... TMF management. EastHORN, a leading European contract research ... increase transparency to enable greater collaboration with sponsors, ...
(Date:9/23/2017)... Sept. 22, 2017 Janssen Biotech, Inc. (Janssen) ... letter from the U.S. Food and Drug Administration (FDA) ... sirukumab for the treatment of moderately to severely active ... clinical data are needed to further evaluate the safety ... active RA. ...
Breaking Medicine Technology: